These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38941890)

  • 1. Histone deacetylases and inhibitors in diabetes mellitus and its complications.
    Wang L; Bai Y; Cao Z; Guo Z; Lian Y; Liu P; Zeng Y; Lyu W; Chen Q
    Biomed Pharmacother; 2024 Aug; 177():117010. PubMed ID: 38941890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.
    Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R
    Cells; 2021 May; 10(6):. PubMed ID: 34071497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues.
    Kumar KK; Aburawi EH; Ljubisavljevic M; Leow MKS; Feng X; Ansari SA; Emerald BS
    Clin Epigenetics; 2024 Jun; 16(1):78. PubMed ID: 38862980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention.
    Khan S; Jena G
    Epigenomics; 2015; 7(4):669-80. PubMed ID: 26111036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.
    Christensen DP; Dahllöf M; Lundh M; Rasmussen DN; Nielsen MD; Billestrup N; Grunnet LG; Mandrup-Poulsen T
    Mol Med; 2011; 17(5-6):378-90. PubMed ID: 21274504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenylbutyrate and β-cell function: contribution of histone deacetylases and ER stress inhibition.
    Khan S; Komarya SK; Jena G
    Epigenomics; 2017 May; 9(5):711-720. PubMed ID: 28470097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classical HDACs in the regulation of neuroinflammation.
    Dai Y; Wei T; Shen Z; Bei Y; Lin H; Dai H
    Neurochem Int; 2021 Nov; 150():105182. PubMed ID: 34509559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
    Wahi A; Jain P; Sinhari A; Jadhav HR
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors as antidiabetic agents: Advances and opportunities.
    Sonthalia M; Roy BS; Chandrawanshi D; Ganesh GV; Jayasuriya R; Mohandas S; Rajagopal S; Ramkumar KM
    Eur J Pharmacol; 2022 Nov; 935():175328. PubMed ID: 36257383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylases (HDACs) as therapeutic target for depressive disorders.
    Misztak P; Pańczyszyn-Trzewik P; Sowa-Kućma M
    Pharmacol Rep; 2018 Apr; 70(2):398-408. PubMed ID: 29456074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylases in cardiovascular and metabolic diseases.
    Bagchi RA; Weeks KL
    J Mol Cell Cardiol; 2019 May; 130():151-159. PubMed ID: 30978343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future Considerations.
    Garmpis N; Damaskos C; Garmpi A; Nonni A; Georgakopoulou VE; Antoniou E; Schizas D; Sarantis P; Patsouras A; Syllaios A; Vallilas C; Koustas E; Kontzoglou K; Trakas N; Dimitroulis D
    Curr Med Chem; 2022; 29(17):2979-2994. PubMed ID: 34525905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.
    Bassett SA; Barnett MP
    Nutrients; 2014 Oct; 6(10):4273-301. PubMed ID: 25322459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
    Falkenberg KJ; Johnstone RW
    Nat Rev Drug Discov; 2014 Sep; 13(9):673-91. PubMed ID: 25131830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy.
    Kumar S; Attrish D; Srivastava A; Banerjee J; Tripathi M; Chandra PS; Dixit AB
    Expert Opin Ther Targets; 2021 Jan; 25(1):75-85. PubMed ID: 33275850
    [No Abstract]   [Full Text] [Related]  

  • 20. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
    Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.